Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E94.02 EPS (ttm)2.43 Insider Own2.30% Shs Outstand341.68M Perf Week-2.74%
Market Cap78.06B Forward P/E14.12 EPS next Y16.18 Insider Trans-35.84% Shs Float334.47M Perf Month-12.97%
Income831.00M PEG3.03 EPS next Q2.70 Inst Own66.80% Short Float0.94% Perf Quarter-2.95%
Sales9.26B P/S8.43 EPS this Y198.90% Inst Trans20.64% Short Ratio1.80 Perf Half Y14.98%
Book/sh18.69 P/B12.22 EPS next Y39.14% ROA2.40% Target Price52.38 Perf Year94.74%
Cash/sh2.80 P/C81.49 EPS next 5Y31.00% ROE14.30% 52W Range111.41 - 263.81 Perf YTD59.65%
Dividend- P/FCF41.13 EPS past 5Y19.20% ROI8.40% 52W High-13.40% Beta1.21
Dividend %- Quick Ratio1.20 Sales past 5Y58.70% Gross Margin74.00% 52W Low105.07% ATR8.97
Employees16800 Current Ratio1.50 Sales Q/Q33.90% Oper. Margin32.30% RSI (14)44.63 Volatility3.46% 4.10%
OptionableYes Debt/Eq4.80 EPS Q/Q-140.50% Profit Margin9.00% Rel Volume0.85 Prev Close232.18
ShortableYes LT Debt/Eq4.71 EarningsJul 23 BMO Payout0.00% Avg Volume1.75M Price228.47
Recom3.00 SMA20-3.75% SMA50-4.34% SMA20014.21% Volume1,485,526 Change-1.60%
Jul-27-15Reiterated Morgan Stanley Overweight $235 → $284
May-26-15Reiterated RBC Capital Mkts Outperform $249 → $265
Apr-30-15Reiterated UBS Buy $222 → $240
Apr-30-15Reiterated Stifel Buy $230 → $250
Apr-30-15Reiterated RBC Capital Mkts Outperform $239 → $249
Apr-30-15Reiterated Cantor Fitzgerald Buy $222 → $271
Feb-25-15Reiterated CRT Capital Buy $180 → $220
Feb-24-15Reiterated UBS Buy $165 → $222
Feb-24-15Reiterated Stifel Buy $175 → $230
Feb-12-15Reiterated RBC Capital Mkts Outperform $188 → $191
Feb-09-15Initiated Barclays Overweight $200
Jan-09-15Reiterated UBS Buy $155 → $165
Feb-28-14Reiterated UBS Buy $141 → $170
Feb-28-14Reiterated RBC Capital Mkts Outperform $151 → $158
Feb-27-14Reiterated Aegis Capital Buy $160 → $180
Jan-08-14Reiterated UBS Buy $125 → $141
Jan-08-14Reiterated Ladenburg Thalmann Buy $123 → $155
Jan-08-14Reiterated FBR Capital Outperform $130 → $153
Dec-03-13Reiterated UBS Buy $115 → $125
Nov-01-13Reiterated Ladenburg Thalmann Buy $127 → $123
Sep-03-15 01:36PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Synergetics USA, Inc. of Commencement of an Investigation Concerning the Fairness of the Sale of the Company to Valeant Pharmaceuticals International, Inc. -- SURG PR Newswire
10:36AM  Moody's: Outlook for global pharmaceutical industry shifts to positive on successful product launches at Moody's
09:50AM  AstraZeneca Ties Up for FluMist, CAZ-AVI Scores; Shares Up
Sep-02-15 07:09PM  SYNERGETICS USA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire
05:12PM  Harwood Feffer LLP Announces Investigation of Synergetics USA, Inc. PR Newswire
04:40PM  AstraZeneca Strikes Deal with Valeant for Psoriasis Drug
04:35PM  Canadian Stocks Rebound From 2-Day Slide as Global Selloff Eases at Bloomberg
11:12AM  The 3 Best Investments Bill Ackman Ever Made at Investopedia
10:37AM  Why Valeant Splurged $1 Billion on Sprout... and Why It's Worth It at Motley Fool
09:59AM  Synergetics USA (SURG) Stock Soars After Being Acquired by Valeant at TheStreet
09:53AM  Valeant Pharmaceuticals (VRX) Stock Climbs on Synergetics Deal at TheStreet
09:25AM  Valeant Agrees to Acquire Synergetics at The Wall Street Journal
09:00AM  Valeant to buy ophthalmic surgical device maker Synergetics
08:50AM  Synergetics to be acquired by Valeant Pharmaceuticals at bizjournals.com
08:50AM  Morning Movers: Wells Fargo Jumps on Upgrade; Navistar Tumbles on Big Earnings Miss at Barrons.com
08:00AM  Valeant Pharmaceuticals To Acquire Synergetics USA PR Newswire
08:00AM  Valeant Pharmaceuticals To Acquire Synergetics USA CNW Group
08:00AM  Synergetics USA to Be Acquired by Valeant Pharmaceuticals Marketwired
Sep-01-15 05:34PM  Valeant steps in to work on psoriasis drug with AstraZeneca
04:50PM  Valeant and Dollar Tree are big market movers
10:50AM  Valeant Buys Abandoned AstraZeneca Psoriasis Drug at Investor's Business Daily
09:19AM  Apple original content; Dollar Tree profit miss; Penn West cuts; Whirlpool bid
08:00AM  Valeant buys psoriasis drug
03:36AM  Valeant picks up AstraZeneca psoriasis drug after Amgen exit Reuters
02:00AM  Valeant And AstraZeneca To Partner On Brodalumab PR Newswire
02:00AM  Valeant And AstraZeneca To Partner On Brodalumab CNW Group
Aug-29-15 08:02AM  4 IBD 50 Drugmakers Getting Lift From New Treatments at Investor's Business Daily
Aug-28-15 12:23PM  Summer M&A Market Sizzles on Pharmaceutical Moves
09:30AM  Ackman Still Confident Herbalife Ltd. (HLF) Will Fall; Discusses Mondelez International Inc (MDLZ), Valeant Pharmaceuticals Intl Inc (VRX) at Insider Monkey
Aug-27-15 06:49PM  Good Watch List Fodder: Mobileye, Essent, Valeant at Investor's Business Daily
03:55PM  Sucampo to Acquire R-Tech Ueno for About $278 Million
08:00AM  Contact lens makers see their day in court
Aug-26-15 11:51AM  Valeant Pharmaceuticals (VRX) Charts Read Like a Textbook Bull at TheStreet
Aug-25-15 04:50PM  Exelixis' Cancer Drug Gets Breakthrough Therapy Status
03:06PM  Gilead Leads 4 Drugmakers In Top Sector Performers at Investor's Business Daily
11:15AM  Lou Simpson Boosts Stake in Charles Schwab
09:29AM  Top 10 Funds & Stocks at Risk of Being Squeezed in Market Turmoil
08:40AM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial
08:00AM  Valeant Pharmaceuticals Announces The Addition Of D. Robert Hale To Its Board Of Directors PR Newswire
08:00AM  Valeant Pharmaceuticals Announces The Addition Of D. Robert Hale To Its Board Of Directors CNW Group
Aug-24-15 12:07PM  10 Stocks Billionaire John Paulson Is Buying in 2015 at TheStreet
09:33AM  Valeant (VRX) Is in Oversold Territory: What's Next?
08:42AM  Apple and 4 Other Stocks Hedge Funds Hated Last Quarter at TheStreet
07:41AM  The Berkshire Hathaway of Biotech Strikes Again at Motley Fool
Aug-22-15 07:03AM  Valeant Bets Women's Viagra Is Worth More Than $1 Billion at Motley Fool
Aug-21-15 04:30PM  Is Valeant's (VRX) $1B Buy of Addyi Maker a Prudent Move?
02:30PM  Fortune Live for August 21, 2015: Fastest-Growing Companies, Change the World, and Hain Celestial at Fortune
12:05PM  5 Stocks Hedge Funds Loved in the Second Quarter at TheStreet
10:10AM  Company News for August 21, 2015
09:53AM  Valeant Pharmaceuticals acquires Sprout Pharmaceuticals at Investopedia
07:09AM  Sprout Pharma CEO Cindy Whitehead reflects on a whirlwind week at bizjournals.com
06:40AM  Here's What Bill Ackman Has Been Buying and Selling at Motley Fool
Aug-20-15 05:58PM  Valeant To Buy Addyi Maker Sprout, But Stock Wilts at Investor's Business Daily -6.47%
05:25PM  Valeant had the hots for female Viagra, Sprout CEO says at Fortune
05:19PM  Valeant to spend about $1B on maker of women's libido drug
04:45PM  Inovio Reports Encouraging Preclinical Data on DNA Vaccine
04:25PM  Valeant buys maker of 'female Viagra' for $1 billion at USA TODAY
04:04PM  Valeant: Low Valuation, Rip-Roaring Growth at Barrons.com
03:24PM  Valeant bets on pink pill
03:23PM  Valeant To Buy Addyi Maker Sprout, But Stock Wilts at Investor's Business Daily
03:20PM  Valeant to Buy Maker of Women's Libido Drug for $1 Billion at The Wall Street Journal
02:43PM  Valeant Spends $1 Billion Buying 'Women's Viagra' -- But Should You Buy Valeant? at TheStreet
02:04PM  Using ETFs To Run Your Own Hedge Fund
01:49PM  Valeant buys maker of 'female Viagra' for $1bn at Financial Times
01:14PM  Valeant and Sprout: neither hot nor bothered at Financial Times
12:47PM  Valeant Pharmaceuticals' New Female Drug
12:16PM  4 Stocks, 4 trades: VRX, LLY, GPRO & LB
12:04PM  Valeant Pharmaceuticals International, Inc -- Moody's: Valeant's acquisition of Sprout delays deleveraging at Moody's
11:51AM  Valeant to Buy Female Libido-Drug Maker Sprout
11:41AM  Valeant soft on Sprout, NetApp up on guidance, Lumber Liquidators higher on hire
11:20AM  Valeant Pays $1B for 'Female Viagra' Maker Sprout Pharmaceuticals at TheStreet
11:00AM  Valeant to spend about $1B on maker of women's libido drug at Los Angeles Times
10:40AM  Stocks Open In Crumple Zone; Valeant Slides, Tech Data Spikes at Investor's Business Daily
10:39AM  Valeant to buy "female Viagra" maker Sprout Pharma
10:35AM  U.S. Markets Fall by 1% as Part of Global Selloff
10:15AM  Why Valeant's acquisition of Sprout could play out differently than Salix deal at bizjournals.com
10:06AM  Valeant's Plan: Take 'Female Viagra' Global at The Wall Street Journal
10:01AM  Valeant, Eli Lilly, NetApp: Stock Market Movers
09:30AM  Billionaire Paulsons Top Healthcare Picks Include Allergan PLC (AGN), Valeant Pharmaceuticals Intl Inc (VRX) & Shire PLC (ADR) (SHPG) at Insider Monkey
09:11AM  Stock Futures Log Heavy Losses; Valeant, Disney, Visa In Motion at Investor's Business Daily
08:50AM  MSG, NetApp rise on quarterly results; Salesforce, Gap on deck at MarketWatch
08:45AM  Why Valeant Pharmaceuticals (VRX) Isn't Done Growing Earnings Yet
08:42AM  Valeant snaps up Female Viagra maker Sprout for $1 billion at Fortune
08:42AM  Stock Futures Slide as Crude Oil Struggles to Hold $40 at TheStreet
08:39AM  What You Need to Know for Wednesday's Market
08:07AM  Sprout Turns Female Libido-Drug Into $1B Valeant Deal
08:06AM  Sprout Turns Female Libido-Drug Into $1B Valeant Deal at Bloomberg
07:53AM  Valeant to Purchase Female Libido-Drug Maker Sprout
07:49AM  Stocks sinking worldwide; Weather Channel on the block; $1B for 'Female Viagra' maker
07:35AM  Is Valeant About to Buy Maker of Female Viagra? at 24/7 Wall St.
07:32AM  Valeant buys Sprout in $1 billion cash deal
07:28AM  Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals PR Newswire
07:28AM  Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals CNW Group
06:42AM  Is new 'pink pill' the new blue?
06:03AM  Valeant to buy female libido drug-maker for $1B at CNBC
01:15AM  Valeant nears deal for 'female Viagra' maker Sprout: WSJ
12:21AM  Valeant nears deal for "female Viagra" maker Sprout Pharmaceuticals - WSJ
Aug-18-15 04:30PM  AVEO Up on Novartis Collaboration for Cachexia Candidate
03:51PM  A Look At Bill Ackman's Super-Concentrated Equity Portfolio
03:11PM  John Paulson Betting On Healthcare And Consumer Discretionary Stocks
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Farmer Ronald HaroldDirectorAug 26Buy220.00500110,0002,000Aug 27 04:33 PM
Farmer Ronald HaroldDirectorAug 21Buy224.971,000224,9731,500Aug 25 04:47 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 31Buy257.25704181,104441,675Aug 03 04:54 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 30Buy253.997,1711,821,362440,971Aug 03 04:54 PM
Rosiello Robert L.Executive Vice PresidentJun 12Buy232.5112,9002,999,37912,900Jun 16 04:01 PM
UBBEN JEFFREY WDirectorJun 10Sale220.244,200,000925,011,6131,059,793Jun 12 07:23 PM
Farmer Ronald HaroldDirectorJun 09Buy232.05500116,025500Jun 10 05:02 PM
Farmer Ronald HaroldDirectorJun 08Buy289.20500144,60035,426Jun 10 05:02 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Option Exercise51.0114,900760,04951,575Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Sale238.0037,9009,020,31813,675Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Option Exercise51.011005,10136,775Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Sale240.0010024,00036,675Jun 03 05:45 PM
Whitaker Anne ClemDirectorMay 26Buy234.677,5001,760,0007,500May 27 04:29 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 05Option Exercise6.1021,807133,02364,994May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Option Exercise25.4290,9382,311,644134,125May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Sale222.5490,93820,237,44343,187May 06 05:51 PM
Kornwasser LaizerEVP, Company Group ChairmanApr 17Option Exercise0.0045,0000123,377Apr 21 05:46 PM
Mirovsky PavelPresident, EMENAApr 15Option Exercise0.0024,175034,175Apr 17 05:28 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 03Option Exercise6.1021,808133,02943,187Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Option Exercise25.4290,9392,311,669112,296Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Sale200.0190,93918,189,09121,379Mar 04 05:24 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMEAFeb 27Option Exercise0.0010,000010,000Mar 02 05:16 PM
Stolz Brian M.EVP, Administration and CHCOJan 22Option Exercise0.007,350095,934Jan 26 05:22 PM
Schiller Howard BradleyEVP, Chief Financial OfficerJan 05Option Exercise0.0045,0000318,714Jan 07 05:38 PM
Stolz Brian M.EVP, CHCO and AdministrationDec 23Option Exercise0.0015,426096,618Dec 24 10:31 AM
Farmer Ronald HaroldDirectorDec 12Buy160.4850080,24033,004Dec 16 02:59 PM
UBBEN JEFFREY WDirectorDec 10Buy139.2950,0006,964,50018,030,936Dec 11 06:59 PM
UBBEN JEFFREY WDirectorDec 09Buy140.25200,00028,050,00017,980,936Dec 11 06:59 PM
STEVENSON KATHARINE BERGHUISDirectorDec 03Buy145.731,500218,59523,098Dec 03 04:48 PM
UBBEN JEFFREY WDirectorNov 24Buy142.25210,00029,872,50017,780,936Nov 26 04:11 PM
Farmer Ronald HaroldDirectorNov 24Buy163.951,000163,95032,504Dec 01 05:25 PM
Stolz Brian M.EVP, Administration and CHCOOct 10Option Exercise0.003,675084,791Oct 14 02:51 PM
Schiller Howard BradleyEVP and CFOOct 03Option Exercise0.0022,5000285,500Oct 07 04:19 PM
Stolz Brian M.EVP, Administration and CHCOSep 30Option Exercise0.0023,030093,064Oct 02 03:52 PM